GLP-1 receptor agonists, which as the glucose-lowering therapeutic agents in the treatment of type 2 diabetes mellitus, have been shown to affect the incidence of cardiovascular outcomes in patients with type 2 diabetes mellitus, although the results regarding GLP-1 receptor agonists remain inconsistent [3, 4]. The gene discussed is GLP1R; the disease is diabetes mellitus.